Association of Intravitreal Anti–Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

Association of Intravitreal Anti–Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration

Published:2019-05-01 Issue:5 Volume:137 Page:483
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Dalvin Lauren A.¹,Starr Matthew R.¹,AbouChehade Jackson E.¹,Damento Gena M.²,Garcia Maria²,Shah Saumya M.²,Hodge David O.³,Meissner Irene⁴,Bakri Sophie J.¹,Iezzi Raymond¹

Affiliation:

1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota

2. Mayo Clinic School of Medicine, Rochester, Minnesota

3. Department of Health Sciences Research/Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida

4. Department of Neurology, Mayo Clinic, Rochester, Minnesota

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

http:///jamaophthalmology/article-pdf/137/5/483/17575413/jamaophthalmology_dalvin_2019_oi_180114.pdf

Reference39 articles.

1. Management of retinal vascular diseases: a patient-centric approach.;Brand;Eye (Lond),2012

2. How the comparison of age-related macular degeneration treatments trial results will impact clinical care.;Davis;Am J Ophthalmol,2011

3. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.;Martin;Ophthalmology,2012

4. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.;Avery;Br J Ophthalmol,2014

5. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration;Park;Int Ophthalmol

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: a World Health Organization pharmacovigilance study;Ophthalmology;2024-07

2. Cardiovascular risk in anti-VEGF treatment of neovascular age-related macular degeneration;Canadian Journal of Ophthalmology;2024-06

3. VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration;Ophthalmology Science;2024-05

4. Systemic adverse events and all-cause mortality following same-session bilateral intravitreal anti-VEGF injections: a systematic review;Graefe's Archive for Clinical and Experimental Ophthalmology;2024-01-09

5. Intravitreal ranibizumab injection is associated with an increased risk of chronic kidney disease: a population-based study in Taiwan;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-12-28